Dose Optimization in 3D Pulsed Dose Rate Brachytherapy for Patients With Locally Advanced Cervical Cancer

• Status: Completed
• Trial end date: 2019-07-01
• Target enrollment: 0
• Participant gender: Female

Summary

This prospective phase II trial study aims to optimize the increase in dose to the target volume at high risk (85 to 90 Gy over 90% of its volume) and the intermediate target volume (60 Gy to 90 % of its volume) in 3D Pulsed Dose Rate Brachytherapy in treating patients with locally advanced cervical cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Institut de Cancérologie de Lorraine
• Treatments: Cisplatin

Criteria

Inclusion Criteria:

• primitive cervical cancer

• adenocarcinoma histologically advanced

• IB2, II and III stage

• curative treatment

• indication of utero-vaginal brachytherapy with external radiotherapy

• non-metastatic tumor and life expectancy > 6 months

• patient informed and follow possible

• performance status ≤ 2

• unplanned surgery

• age ≥ 18 years old

• ability to provide written informed consent before the start of any study specific procedures

Exclusion Criteria:

• primitive endometrial cancer

• other diseases

• carcinoma in situ and stages ≤ B

• distant metastases

• history of pelvic irradiation or a first pelvic cancer

• contraindication to MRI

• history of subtotal or total hysterectomy

• pregnant or breast feeding females

• inability to support low dose rate continuous brachytherapy or pulsed flow

• person in emergencies

• person unable to give personally consent

• patient participating in another clinical research except in case of local recurrence or observational research